10q10k10q10k.net
LISATA THERAPEUTICS, INC.

LISATA THERAPEUTICS, INC.LSTAEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.

Q4 2025Q3 2025Q2 2025Q1 2025Q3 2024Q2 2024Q1 2024

Revenue

$0

Gross Profit

N/A

Operating Profit

$-5.5M

Net Profit

$-5.0M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.61

LISATA THERAPEUTICS, INC. Q2 FY2024 Financial Summary

LISATA THERAPEUTICS, INC. reported revenue of $0 for Q2 FY2024, with a net profit of $-5.0M (down 25.3% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-5.0M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ2 FY2024

LISATA THERAPEUTICS, INC. Annual Revenue by Year

LISATA THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $170.0K).

YearAnnual Revenue
2025$170.0K

LISATA THERAPEUTICS, INC. Quarterly Revenue & Net Profit History

LISATA THERAPEUTICS, INC. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$100.0K-90.0%N/AN/A
Q3 FY2025$0—$-4.2MN/A
Q2 FY2025$70.0K—$-4.7M-6655.7%
Q1 FY2025$0—$-4.7MN/A
Q3 FY2024$0—$-4.9MN/A
Q2 FY2024$0—$-5.0MN/A
Q1 FY2024$0—$-5.4MN/A

Income Statement

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue$0$0$0$0$70000$0$100000
YoY GrowthN/AN/AN/AN/AN/AN/A-90.0%

Balance Sheet

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025Q4 2025
Assets$48.2M$42.6M$38.2M$29.0M$25.2M$21.8M$17.7M
Liabilities$5.5M$4.6M$4.8M$3.9M$4.4M$4.6M$3.1M
Equity$43.0M$38.2M$33.7M$25.4M$21.0M$17.4M$14.9M

Cash Flow

Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$-7.0M$-5.3M$-2.5M$-5.4M$-4.0M$-3.3M$-15.9M